RAW-LABS
11.2.2021 18:14:10 CET | Business Wire | Press release
RAW Labs , today announced it has completed a USD 5.5M pre-A funding round raising capital from new and existing investors to support the surge in demand for its revolutionary data management solution. The company also announced Lars Farnstrom as its new CEO.
The financing round was led by a group of investors specializing in investments of high growth technology companies and Investiere.ch. The funding will enable RAW Labs to accelerate the acquisition of large enterprise clients and continue investing in the expansion of the capabilities of its core NoDB data platform. Claude Honegger (former global CIO of Credit Suisse) and Pyrros Koussios (former private equity investor and senior executive at international technology companies) are joining the board of directors.
“We are excited that Lars has accepted the CEO role. His long experience in enterprise software from companies like Siebel Systems and C3.ai is a tremendous asset and will enable us to take RAW Labs to the next level,” said Ariel Luedi, one of the founding investors of RAW Labs and former CEO of SAP Hybris. Professor Anastasia Ailamaki, co-founder of RAW Labs, will continue as Chief Scientific Officer with the mission to strengthen the company’s research into groundbreaking data management technologies.
RAW Labs’ NoDB is a platform for data engineers, data scientists, and data analysts to seamlessly access, query, clean, and enhance heterogeneous data sources in near real time and transform them into high-value data products for consumption by analytical tools, ML-models, and enterprise applications.
What makes RAW NoDB unique is its revolutionary query engine, which unlike any other solution in the market uses Category Theory. This gives RAW the unique capability to query large and complex data sources at high performance without the need for any costly and time-consuming ETL/ELT preprocessing or integration with data sources.
“It’s a privilege to have a group of sophisticated investors who have proven experience in helping technology companies scale,” said Lars Farnstrom, CEO of RAW Labs. “Data drives digital transformation. We believe that by eliminating the artificial barrier between operational and analytical data, and by enabling this in record time and without any expensive integrations, RAW Labs can help companies accelerate their digital transformation. Just connect your data sources and start asking questions that will help you unlock new insights on how to reduce costs or increase sales.”
About RAW Labs
RAW Labs, an École Polytechnique Fédérale de Lausanne (EPFL) spinout, helps companies unlock the value of data by providing a single unified platform to effortlessly access and convert any data source into data products for new insights and better decision making, at a fraction of the time and cost of traditional solutions. RAW is available on premise, in the cloud, or in hybrid mode.
For more information, visit https://www.raw-labs.com
View source version on businesswire.com: https://www.businesswire.com/news/home/20210211005738/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
FPT Named an OpenAI Select Partner6.8.2026 02:00:00 CEST | Press release
Global IT corporation FPT today announced that it has been named an OpenAI Select Partner within the OpenAI Partner Network. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260805503787/en/ FPT Named an OpenAI Select Partner The OpenAI Partner Network is a global program for partners to build, sell, and deliver AI solutions with OpenAI. It brings together partners with deep industry expertise, delivery capabilities, and customer relationships while equipping them with resources, enablement, and support to help enterprises adopt OpenAI frontier models and products and turn them into measurable impact. As an OpenAI Select Partner, FPT will continue working with OpenAI to help organizations build, deploy, and scale AI solutions responsibly and effectively. This work will help organizations get more useful work from every token and stronger performance per dollar with GPT‑5.6, while using ChatGPT Work to turn ambitious goals into
U.S. FDA Approves Takeda’s ORZEYFUL™ (oveporexton), the First and Only Medicine to Treat the Underlying Cause of Narcolepsy Type 16.8.2026 00:10:00 CEST | Press release
Adults Taking ORZEYFUL Experienced Significant and Meaningful Improvements Across the Full Range of Symptoms of Narcolepsy Type 1 (NT1) in Clinical Trials Compared to Those on Placebo As a First-in-Class Orexin Treatment, ORZEYFUL has the Potential to Redefine NT1 Care Beyond Individual Symptoms Takeda is Advancing U.S. Launch Preparations and Expects to Make ORZEYFUL Available Following Completion of the Drug Enforcement Administration (DEA) Scheduling Process Takeda (TSE:4502/NYSE:TAK) announced that the U.S. Food and Drug Administration (FDA) approved ORZEYFUL™ (oveporexton), an oral orexin receptor 2 (OX2R) agonist, for the treatment of narcolepsy type 1 (NT1, narcolepsy with cataplexy) in adults.* The persistent 24-hour nature of NT1 is driven by orexin deficiency and can severely impact people’s lives. As a first-in-class orexin treatment, ORZEYFUL is the only medicine indicated in the U.S. to treat the disease holistically rather than individual symptoms. “The FDA approval of OR
Compass Pathways Announces New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)5.8.2026 22:30:00 CEST | Press release
Compass Pathways plc (Nasdaq: CMPS), a biotechnology company dedicated to unlocking urgently needed new treatment options in mental health care, announced today that Compass granted equity awards under the Compass Pathways plc 2026 Inducement Plan to fourteen newly hired non-executive employees. The equity awards were granted on August 3, 2026 and consisted of options to purchase an aggregate of 139,355 shares and restricted share units or, in the case of employees in the United Kingdom nominal cost options, covering an aggregate of 66,300 shares. The options have an exercise price per share equal to $11.25, the closing price of the Company’s American Depositary Shares on the Nasdaq Global Select Market on the grant date, and will vest over a four-year period with 25% vesting on the first anniversary of the date of the grant and the remaining 75% vesting in equal monthly installments over the three-year period thereafter, subject to each employee’s continued employment. The restricted
Clinilabs Announces Medical Leadership Appointments5.8.2026 16:05:00 CEST | Press release
Bob Dagher, M.D., Named Chief Medical Officer and Waqar Ahmed Siddiqui, M.D., Named Principal Investigator Clinilabs (“Clinilabs LLC”), a global, full-service contract research organization (CRO) specializing in central nervous system (CNS) drug and device development, today announced the appointments of Bob Dagher, M.D., as Chief Medical Officer and Waqar Ahmed Siddiqui, M.D., as Principal Investigator of the Company’s Eatontown, New Jersey Clinical Research Unit (CRU). Dr. Dagher will provide strategic and medical leadership across the organization, while Dr. Siddiqui will lead the execution of research projects at the Company’s CRU. Together, they will support the design, development, and execution of clinical programs for pharmaceutical, biotechnology, and medical device sponsors advancing innovative therapies for psychiatric, neurological, substance use, and rare CNS disorders. “Clinilabs has earned the trust of sponsors by combining deep scientific expertise, medical leadership,
Interactive Brokers Adds Brazilian Futures through Brazil’s B3 Exchange5.8.2026 16:00:00 CEST | Press release
Interactive Brokers (Nasdaq: IBKR), an automated global broker, today announced that eligible clients outside of Brazil can now trade Brazilian futures in addition to equities through the B3 exchange. Interactive Brokers was the first broker to provide international investors with streamlined, low-cost access to B3. Offering Brazilian futures and equities alongside products across more than 170 markets worldwide underscores IBKR’s commitment to broadening global market access and giving clients efficient, cost-effective ways to diversify through a single, unified platform. Access to B3 provides exposure to one of Latin America’s most active and liquid markets, providing long-term growth potential across multiple sectors and another way for investors to pursue emerging market opportunities. "Global investors deserve seamless, low-cost access to the world's most compelling markets, including emerging economies shaping tomorrow's financial landscape," said Milan Galik, Chief Executive Off
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom